Cargando…

Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma

Mouse models of human cancer provide an important research tool for elucidating the natural history of neoplastic growth and developing new treatment and prevention approaches. This is particularly true for multiple myeloma (MM), a common and largely incurable neoplasm of post-germinal center, immun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pisano, Michael, Cheng, Yan, Sun, Fumou, Dhakal, Binod, D’Souza, Anita, Chhabra, Saurabh, Knight, Jennifer M., Rao, Sridhar, Zhan, Fenghuang, Hari, Parameswaran, Janz, Siegfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206561/ https://www.ncbi.nlm.nih.gov/pubmed/34149703 http://dx.doi.org/10.3389/fimmu.2021.667054

Ejemplares similares

Germline Risk Contribution to Genomic Instability in Multiple Myeloma
por: Janz, Siegfried, et al.
Publicado: (2019)

WDR26 and MTF2 are therapeutic targets in multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2021)

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Prevalence and Significance of Sarcopenia in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
por: Williams, Alexis, et al.
Publicado: (2020)

FOXM1 regulates glycolysis and energy production in multiple myeloma
por: Cheng, Yan, et al.
Publicado: (2022)

Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study
por: Buradagunta, Christopher Staffi, et al.
Publicado: (2022)

Recent advances in understanding multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2016)

Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study
por: Dong, Jing, et al.
Publicado: (2022)

A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy
por: Kleman, Ariel, et al.
Publicado: (2023)

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2019)

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
por: Hammons, Lindsay R., et al.
Publicado: (2022)

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis
por: D'Souza, Anita, et al.
Publicado: (2017)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)

Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial
por: D'Souza, Anita, et al.
Publicado: (2020)

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2018)

Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019)

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol
por: Johnson, Alexander K., et al.
Publicado: (2022)

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL
por: Costa, Luciano, et al.
Publicado: (2023)

A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics
por: Awada, Hassan, et al.
Publicado: (2021)

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
por: Yang, Ye, et al.
Publicado: (2014)

IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma
por: Pisano, Michael D., et al.
Publicado: (2023)

Development of Novel Immunotherapies for Multiple Myeloma
por: Al-Hujaily, Ensaf M., et al.
Publicado: (2016)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018)

Immunopathology and Immunotherapy of Inflammatory Skin Diseases
por: Song, Ahreum, et al.
Publicado: (2022)

CoViD-19 Immunopathology and Immunotherapy
por: Chiappelli, Francesco, et al.
Publicado: (2020)

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma
por: Han, Seong-Su, et al.
Publicado: (2015)

Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse
por: Dhakal, Binod, et al.
Publicado: (2022)

Microbes as Master Immunomodulators: Immunopathology, Cancer and Personalized Immunotherapies
por: Lérias, Joana R., et al.
Publicado: (2020)

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation
por: Knight, Jennifer M., et al.
Publicado: (2018)

Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen
por: Palmen, Breanna, et al.
Publicado: (2023)

Pretransplant Splenic Irradiation in Patients With Myeloproliferative Neoplasms
por: Ponce, Sara Beltrán, et al.
Publicado: (2022)

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
por: Cheng, Yan, et al.
Publicado: (2023)

HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA
por: Jiang, Fengjie, et al.
Publicado: (2021)

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2021)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
por: Wu, James F., et al.
Publicado: (2023)

Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies
por: Mohan, Meera, et al.
Publicado: (2022)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mkcnrdho47lk0842b5goefi0un